The results of the randomized DETECT III trial suggested that Lapatinib resulted in early declines in circulating tumor cell counts (CTCs) in patients with initially HER2-negative metastatic breast cancer but HER2-positive CTCs [49]. The gene discussed is ERBB2; the disease is neoplasm.